Regulations.gov document
Patient-Focused Drug Development: Incorporating Clinical OutcomeAssessments Into Endpoints…
Notice · FDA-2023-D-0026 · posted Apr 6, 2023
Key facts
| Document ID | FDA-2023-D-0026-0001 |
|---|---|
| Title | Patient-Focused Drug Development: Incorporating Clinical OutcomeAssessments Into Endpoints for Regulatory Decision-Making; Draft Guidance for Industry, Food and DrugAdministration Staff, and OtherStakeholders; Availability |
| Document type | Notice |
| Subtype | Notice of Availability |
| Agency | FDA |
| Docket | FDA-2023-D-0026 |
| Posted | Apr 6, 2023 |
| Federal Register citation | 88 FR 20530 |
| FR document number | 2023-07243 |
| Comment period opens | Apr 6, 2023 |
| Effective date | Apr 6, 2023 |
At a glance
- None Pages
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: